Core Viewpoint - Junshi Biosciences expects to achieve an annual revenue of approximately 2.5 billion yuan in 2025, representing a year-on-year growth of about 28.32% [1] Revenue and Profit Forecast - The projected R&D expenses are estimated at 1.353 billion yuan, an increase of approximately 6.10% compared to the previous year [1] - The expected net profit attributable to shareholders is a loss of approximately 873 million yuan, which is a reduction in losses compared to the previous year [1] - After excluding the impact of share-based payments, the expected net profit attributable to shareholders is a loss of about 799 million yuan, reflecting a year-on-year decrease in losses of approximately 37.62% [1] - The expected net profit attributable to shareholders, after excluding non-recurring gains and losses, is a loss of about 985 million yuan, which is a reduction in losses of approximately 23.64% [1] Revenue Growth Drivers - The growth in revenue is primarily attributed to the significant increase in sales of the core product, Toripalimab injection (Tuoyi®), in the domestic market [1] - Tuoyi® has been approved for 12 indications, all of which are included in the national medical insurance catalog, and has been approved for sale in multiple countries and regions globally [1] Cost Management and Future Plans - Despite the continued net loss, the company has significantly narrowed the loss amount, mainly due to ongoing efforts in quality improvement and cost control [1] - The company plans to accelerate the clinical trials of several innovative drugs that have competitive advantages in international markets [1]

北京商报讯（记者 丁宁）1月30日晚间，君实生物（688180）发布2025年业绩预告显示，预计2025年实 现归属净利润为-8.73亿元左右，与上年同期相比亏损减少4.08亿元左右，同比亏损减少31.85%左右。 君实生物表示，公司2025年年度归属净利润仍出现亏损，但亏损金额与上年同期相比显著缩窄，主要系 公司持续落实"提质增效重回报"行动方案，商业化能力显著提升的同时不断加强费用管控与资源聚焦。 报告期内，公司在控制费用的同时维持了核心管线的高效推进，正快速推进PD-1/VEGF 双抗（代号： JS207）、EGFR/HER3 ADC（代号：JS212）、PD-1/IL-2融合蛋白（代号：JS213）等多款具有国际市 场竞争力的创新药物的临床试验，并积极探索多种联用方案，以最大程度发挥管线协同作用。 ...

Core Viewpoint - Junshi Biosciences (01877) expects to achieve approximately 2.5 billion yuan in revenue for the year 2025, representing a year-on-year growth of about 28.32% [1] Financial Performance - The projected R&D expenses for 2025 are approximately 1.353 billion yuan, reflecting a year-on-year increase of about 6.10% [1] - The expected net loss attributable to the parent company for 2025 is around 873 million yuan, a reduction of approximately 31.85% compared to the previous year [1] - After excluding the impact of share-based payments, the net loss is projected to be about 799 million yuan, a decrease of approximately 37.62% year-on-year [1] - The net loss after excluding non-recurring gains and losses is expected to be around 985 million yuan, down about 23.64% year-on-year [1] - The net loss after excluding both share-based payments and non-recurring items is projected to be approximately 911 million yuan, a reduction of about 29.37% year-on-year [1] Product and Market Development - The increase in revenue is primarily due to the growth in sales of commercialized drugs, particularly the core product Toripalimab injection (brand name: Tuoyi®), which saw significant sales growth in the domestic market [1] - As of the announcement date, Tuoyi® has been approved for 12 indications in mainland China, all of which are included in the national medical insurance catalog, making it the only anti-PD-1 monoclonal antibody for treating renal cancer, triple-negative breast cancer, and melanoma in the catalog [1] - The company continues to expand its global commercialization network, with Toripalimab approved in over 40 countries and regions, including mainland China, Hong Kong, the United States, the EU, India, the UK, Jordan, Australia, Singapore, the UAE, Kuwait, Pakistan, Canada, and Bahrain [2] Strategic Initiatives - Despite the expected net loss, the company has significantly narrowed its loss compared to the previous year, mainly due to the implementation of the "quality improvement and efficiency enhancement" action plan, which has improved commercialization capabilities while strengthening cost control and resource focus [2] - The company is advancing its core pipeline efficiently while controlling expenses, rapidly progressing clinical trials for several innovative drugs with international market competitiveness, including JS207 (PD-1/VEGF dual antibody), JS212 (EGFR/HER3 ADC), and JS213 (PD-1/IL-2 fusion protein) [2] - JS207 is currently in Phase II clinical trials, exploring combinations with chemotherapy, monoclonal antibodies, ADCs, and other drugs across multiple tumor types, with ongoing Phase II trials for the combination of JS207 and JS212 [2] - The company aims to accelerate pipeline development and push more advantageous products and indications into the registration clinical trial phase as soon as possible [2]

(编辑：杨燕 林辰) （阿斯利康公众号） 1月29日，阿斯利康宣布，计划于2030年前在中国投资逾1000亿元人民币（150亿美元），以扩大在药品 生产与研发领域的布局。公司将充分发挥中国的科研优势和先进制造能力，并依托中英医疗健康生态系 统之间的协同合作，为中国及全球患者带来前沿创新疗法。 阿斯利康全球首席执行官苏博科表示，今天宣布的这笔逾1000亿元人民币的重大投资，开启了阿斯利康 在华发展的新篇章。中国已成为科学创新、先进制造和全球公共卫生领域的重要力量。通过进一步扩展 我们在细胞治疗、放射偶联药物等突破性疗法的能力，阿斯利康将为中国高质量发展作出更大贡献，更 重要的是，把下一代创新疗法带给更多患者。 ...

Core Viewpoint - Teva Biopharma (688278.SH) plans to raise up to 1.533 billion yuan through convertible bonds to enhance its main business, focusing on new drug research and development, biotechnology innovation center construction, and innovative drug production expansion projects [1][2]. Group 1: Fundraising and Investment Plans - The total amount to be raised from the convertible bonds is capped at 1.533 billion yuan, which will be allocated to new drug R&D, biotechnology innovation center construction, and production expansion projects [2][3]. - This marks the first fundraising initiative since the company went public in January 2020, during which it raised 383 million yuan [2]. - The net proceeds from the fundraising will be used to enhance the company's R&D capabilities and expand its product pipeline, thereby strengthening its business scale and risk resilience [2][3]. Group 2: Company Performance and Growth - Teva Biopharma has shown robust performance, with revenue increasing approximately 5.3 times from 448 million yuan in 2018 to 2.817 billion yuan in 2024, and net profit rising over 50 times from 16 million yuan to 828 million yuan during the same period [6]. - In the first three quarters of 2025, the company achieved a revenue of 2.48 billion yuan, a year-on-year increase of 26.85%, and a net profit of 666 million yuan, up 20.21%, both setting historical records for the same period [6]. - The company's gross margin remains high at around 93%, indicating strong profitability [6]. Group 3: Research and Development Focus - Teva Biopharma is committed to R&D, with R&D expenses exceeding 10% of revenue in both 2023 and 2024, and a significant year-on-year increase of 44.48% in R&D expenses to 279 million yuan in the first three quarters of 2025 [1][5]. - The company has successfully developed three Class 1 new biological drugs and is actively pursuing innovative drug development in areas such as small nucleic acid drugs, antibody drugs, mRNA vaccines, and gene therapy [5][6]. - The planned investment in the new drug R&D project is 859 million yuan, focusing on expanding existing core product indications and accelerating the development of innovative drugs [3][4]. Group 4: Strategic Initiatives and Future Outlook - The biotechnology innovation center project aims to enhance the company's capabilities in product innovation, core technology R&D, and technology transfer, with a total investment of 471 million yuan [3]. - The production expansion project is expected to improve the production capacity of the drug Yipeisheng, addressing the growing market demand for treatments related to growth hormone deficiency [3][4]. - Teva Biopharma is also expanding its global footprint by acquiring assets from Skyline Therapeutics Limited, indicating a strategic move towards integrating cutting-edge technology resources [5].

Core Viewpoint - The company emphasizes its diverse product range and ongoing research and development efforts to ensure long-term stable growth [1] Product Lifecycle and Pipeline Development - The company has a rich variety of products covering multiple therapeutic areas, with its main product, Likujun tablets, showing promising applications in the oral white blood cell-boosting drug sector [1] - The company is also developing innovative drugs such as the antidepressant JJH201501 and the anti-tumor drug JJH201601, supported by its research technology platforms including compound formulation, deuterated drug, and liposome drug development technologies [1]

Financial Data and Key Metrics Changes - In Q4 2025, worldwide sales were $24.6 billion, an increase of 7.1% despite a 650 basis point headwind from Stelara [19] - For the full year 2025, worldwide sales reached $94.2 billion, reflecting a 5.3% increase, with U.S. growth at 6.9% and 3.4% outside the U.S. [20][21] - Net earnings for Q4 were $5.1 billion, with diluted earnings per share at $2.10, compared to $1.41 a year ago [20] - Full year adjusted net earnings were $26.2 billion, with adjusted diluted earnings per share at $10.79, an increase of 8.1% compared to 2024 [21] Business Line Data and Key Metrics Changes - Innovative Medicine sales for Q4 were $15.8 billion, up 7.9%, with significant contributions from oncology and immunology [22] - In oncology, Darzalex grew 24.1%, while Carvykti achieved sales of $555 million with 63.2% growth [22] - Tremfya in immunology saw remarkable growth of 65.4%, while Stelara declined 48.6% due to biosimilar competition [23] - MedTech sales for the year were $34 billion, with operational growth of 5.4%, driven by cardiovascular and surgical segments [15][24] Market Data and Key Metrics Changes - In oncology, operational sales growth was 21% in 2025, with expectations to exceed $50 billion in annual sales by 2030 [10] - The cardiovascular segment delivered 15% operational sales growth, with Abiomed and Shockwave showing strong performance [15][16] - Vision care saw robust growth, particularly in surgical vision, with a 10.8% increase driven by new product innovations [17] Company Strategy and Development Direction - The company plans to separate its orthopedics business to focus on high-growth areas [7] - Investments of over $32 billion in R&D and M&A in 2025, including acquisitions of Intra-Cellular Therapies and HALDA Therapeutics, are aimed at accelerating growth [8] - The company aims for double-digit growth by the end of the decade, supported by a diverse portfolio of 28 products generating over $1 billion annually [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in accelerated growth for 2026, driven by a strong portfolio and pipeline [8][30] - The company anticipates operational sales growth of 5.7%-6.7% for 2026, with a midpoint of $100 billion [32] - Management highlighted the importance of innovation in driving future growth, particularly in oncology and immunology [45][50] Other Important Information - The company ended 2025 with approximately $20 billion in cash and marketable securities, generating $19.7 billion in free cash flow [31] - The effective tax rate for Q4 2025 was a benefit of 3%, compared to an 11.7% cost in Q4 2024 [27] - Adjusted income before tax as a percentage of sales increased from 24.1% to 28.7% [28] Q&A Session Summary Question: Overview of growth prospects and strategic repositioning - Analyst inquired about the key levers for achieving double-digit growth and the impact of the orthopedics separation on the company's strategy [43] - Management responded that the focus on oncology, immunology, and MedTech will drive growth, with a strong pipeline supporting this outlook [44][45] Question: MedTech market dynamics and growth expectations - Analyst asked about the MedTech market outlook for 2026 and the performance of the electrophysiology business [53] - Management indicated confidence in growth despite market dynamics, emphasizing strong clinical demand and successful product launches [54][60] Question: Margin progression and relationship to top-line growth - Analyst sought clarification on margin expansion in relation to expected sales growth [62] - Management noted that margin improvements are expected to align with sales growth, particularly post-orthopedic separation [66] Question: Vision care market health and performance - Analyst requested insights on the vision care segment's performance and market dynamics [69] - Management confirmed strong underlying performance in the contact lens category, with a focus on innovation and growth in vision care [70]

Core Viewpoint - The company is focusing on accelerating the development of innovative drugs through its strong oncology research team and strategic global clinical development capabilities, aiming to become a leading innovator in cancer treatment [1]. Group 1: Company Strategy and Development - The company has one of the largest oncology clinical research teams in the industry and is leveraging this to enhance its innovative drug offerings [1]. - In the past 18 months, the company has advanced 15 new molecular entities into clinical development, covering various treatment modalities [1]. - From 2026 onwards, the company expects to introduce 8 to 10 new molecular entities into clinical development each year, signaling a new wave of innovation [1]. Group 2: Pipeline and Future Prospects - Several products in the company's pipeline, including CDK4 inhibitors, B7-H4 ADC, PRMT5 inhibitors, GPC3x41BB bispecific antibodies, and CEA ADC, are expected to enter late-stage clinical development by 2026 [1]. - The company is committed to building a sustainable competitive advantage and will continue to invest in a rich and innovative R&D pipeline [1]. - The company aims to actively seek and execute business expansion opportunities that create long-term value [1].

Teva Pharmaceutical Industries FY Conference Summary Company Overview - **Company**: Teva Pharmaceutical Industries (NYSE: TEVA) - **CEO**: Richard Francis - **Conference Date**: January 13, 2026 Core Industry and Company Strategy - Teva is transitioning from a leading global generics company to a leading biopharma company, a strategy initiated three years ago [2][3] - The "pivot to growth" strategy is based on four pillars: 1. Deliver on growth engines 2. Step up innovation 3. Create a generics powerhouse 4. Focus the business [3] Financial Performance - Teva has achieved 11 consecutive quarters of growth since early 2023, reversing a previous decline [5] - The company is experiencing a transformation in financials, with improvements in gross margin, free cash flow, EBITDA, and operating margin while reducing debt [6][30] - Revenue growth is primarily driven by the innovative business, which has doubled in the last three years [11] Innovative Products and Pipeline - Key innovative products include: - **Austedo**: Revenue expectations have increased from $1.4 billion to potentially $3 billion [9] - **Ajovy**: Targeting $1 billion in revenue with double-digit growth [9] - **Uzedy**: Projected to achieve $1.5-$2 billion in revenue [10] - Teva's pipeline includes several promising products: - **Duvakitug**: Entering phase 3 studies for ulcerative colitis (UC) and Crohn's disease (CD) [4] - **Anle138b**: Treatment for multiple system atrophy (MSA) with a significant unmet need [23] - **Anti-IL-15**: Targeting celiac disease and vitiligo, with multiple indications expected [19][25] Market Position and Competitive Landscape - Teva is positioning itself in high-value markets, including a $9 billion market for schizophrenia treatments [14] - The company aims for over $10 billion in peak sales across its innovative portfolio [13] - Teva's generics business is expected to grow at a low CAGR of 1%-2%, with a focus on biosimilars [26] Future Outlook - Teva anticipates a stable generics business while focusing on innovative growth, with a long-term vision extending over 20 years [5][31] - The company expects to maintain a 30% operating margin and continue growing EBITDA and free cash flow through 2027 [30] - Upcoming product launches include Olanzapine in 2026 and Daria in 2027, with a steady cadence of new products expected [36][38] Key Financial Metrics and Guidance - Revenue for 2026 is projected to be at the lower end of guidance due to the loss of $1.1 billion from generic Revlimid [29][41] - Despite this loss, Teva expects to grow EBITDA and operating margin, indicating a successful transformation of its portfolio [30] Conclusion - Teva is on a transformative journey towards becoming a leading biopharma company, with a strong focus on innovation and a robust pipeline of products that address significant unmet medical needs. The company is well-positioned for future growth, despite challenges in the generics market.

Group 1 - The core point of the article is that Wanbangde's subsidiary has been selected for a national major science and technology project focused on innovative drug development for Alzheimer's disease [2] - The project is led by the Shanghai Institute of Materia Medica, which is part of the Chinese Academy of Sciences [2] - The company has received official approval from the National Health Commission's China Biotechnology Development Center for the project [2]